Medtide Inc. is a biotechnology and medical research company specializing in contract research, development, and manufacturing services, with a primary focus on peptide-based therapeutics. The company operates as a contract research organization (CRO) and contract development and manufacturing organization (CDMO), providing a full spectrum of services ranging from early-stage drug discovery and preclinical research to clinical development and large-scale commercial production. Medtide Inc. leverages proprietary technology platforms such as OmniPeptSynth and PeptiConjuX to enable advanced peptide synthesis, formulation, and impurity screening. Its expertise centers on the development of innovative peptides, including glucagon-like peptide-1 (GLP-1) analogs, which are significant in the treatment of metabolic and endocrine disorders. The company serves a global client base spanning the United States, China, Europe, Japan, South Korea, and Australia. Medtide Inc. plays a vital role in accelerating the development pipeline for pharmaceutical and biotechnology firms, offering specialized capabilities in active pharmaceutical ingredient (API) production that support advancements in healthcare and therapeutic innovation.